Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Study Of Single Ascending Doses Of PBL 1427 In Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01554293
Recruitment Status : Unknown
Verified May 2013 by Panacea Biotec Ltd.
Recruitment status was:  Recruiting
First Posted : March 14, 2012
Last Update Posted : May 16, 2013
Information provided by (Responsible Party):
Panacea Biotec Ltd

Brief Summary:
PBL 1427 is a Dipeptidyl peptidase (DPP)-IV inhibitor being developed for treatment of type 2 diabetes. Although a number of DPP-IV inhibitors have been described, there still exists a need for new DPP-IV inhibitors that have better half-life, advantageous potency, stability and selectivity, less toxicity and/or better pharmacodynamic properties.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus Drug: Matching placebo Drug: PBL 1427 capsules Phase 1

Detailed Description:

As per the randomization schedule, capsule(s) of A or B will be administered to each subject with 240 mL of water at ambient temperature. Subjects will be instructed not to chew or crush the capsule(s) but to consume it as a whole. Compliance for dosing will be assessed by a thorough check of the oral cavity immediately after dosing. Administration of investigational products will be carried out while the subjects are in sitting posture and they will be instructed to remain seated for two hours after dosing except when clinically indicated to change the posture or in case of any natural exigency. Thereafter, the subjects will be allowed to engage in normal activities while avoiding severe physical exertion.

The following treatments in the below cohorts will be followed as given below:

Cohort 1: A single oral dose of 20 mg of PBL 1427 (n=6) or placebo (n=2) Cohort 2: A single oral dose of 40 mg (20 mg X 2 capsules) of PBL 1427 (n=6) or placebo (n=2) Cohort 3: A single oral dose of 80 mg (20 mg X 4 capsules) of PBL 1427 (n=6) or placebo (n=2) Cohort 4: A single oral dose of 150 mg of PBL 1427 (n=6) or placebo (n=2) Cohort 5: A single oral dose of 300 mg (150 mg X 2 capsules) of PBL 1427 (n=6) or placebo (n=2) Cohort 6: A single oral dose of 600 mg (150 mg X 4 capsules) of PBL 1427 (n=6) or placebo (n=2)

Dose levels may be modified and intermediate dose levels might be tested to determine the maximum tolerated dose (MTD)

The number of cohorts, dose levels, frequency and conditions of administration for the subsequent cohort may be altered by the Principal investigator and Sponsor after evaluation of the results of the previous group.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Phase I Study To Determine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Ascending Doses Of PBL 1427 In Healthy Volunteers
Study Start Date : July 2012
Estimated Primary Completion Date : July 2013
Estimated Study Completion Date : September 2013

Arm Intervention/treatment
Experimental: PBL 1427 capsules Drug: PBL 1427 capsules
PBL 1427 capsules 20 mg and 150 mg, single dose

Placebo Comparator: Matching placebo Drug: Matching placebo
Matching Placebo, single dose

Primary Outcome Measures :
  1. Number of subjects with adverse events [ Time Frame: Pre-dose and upto Day 5-9 ]
    Safety and tolerability of PBL 1427 will be assessed after single ascending doses when administered alone on the basis of AEs, vital signs (BP, pulse rate, and body temperature), ECG, laboratory parameters and clinical assessment.

  2. Pharmacokinetics Variables (Cmax, tmax, AUC, t1/2, kel, CL/F & Vz/F) [ Time Frame: 48 hrs post dose ]
    Pharmacokinetic parameters of single ascending doses of PBL 1427 : For each subject, blood will be collected at the following time points: pre-dose, 0.25, 0.50, 0.75 1, 1.5, 2, 3, 4, 6, 8, 10, 14, 16, 20, 24, 36 and 48 h post-dose.

Secondary Outcome Measures :
  1. Pharmacodynamics assessment (glucose, insulin, C-peptide, lactic acid) [ Time Frame: Pre-dose and upto 4 h post-dose ]
    Pharmacodynamics will be assessed using markers like glucose, insulin, C-peptide, lactic acid and the exploratory markers plasma DPP-IV activity and plasma GLP-1 (Glucagon-like peptide I) levels

  2. Exploratory markers (plasma DPP-IV activity and GLP-1 levels) [ Time Frame: Pre-dose and upto 48 h after dosing ]
    Pharmacodynamics will be assessed using markers like glucose, insulin, C-peptide, lactic acid and the exploratory markers plasma DPP-IV activity and plasma GLP-1 (Glucagon-like peptide I) levels

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria: Subjects to be enrolled in this trial must fulfil all of these criteria:

  • Sex: male
  • Age: 18-60 yr old, both inclusive
  • Having a Body Mass Index (BMI) between 18.5-28 kg / m2 (both inclusive) and body weight not less than 45 kg
  • Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; and to comply with the requirements of the entire study
  • Voluntarily given written informed consent to participate in this study
  • Be of normal health as determined by the principal investigator from medical history, physical examination and laboratory investigations, 12- lead ECG and X-ray chest of the subjects performed within 10 days prior to the admission of the study
  • Ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, coke, chocolate, "power drinks") and grapefruit (juice) from 48 h prior to each admission until study completion

Exclusion Criteria: Subjects meeting any of these criteria will not be enrolled in the study:

  • Employees of FCRL or PBL
  • Not willing to use contraceptives (preferably condoms) during sexual activity for the period of 3 months from the date of check-in
  • History of hypersensitivity and / or intolerance to Dipeptidyl peptidase (DPP)-IV inhibitors or any other related compounds.
  • History of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study.
  • Clinically abnormal ECG and Chest X-ray.
  • Physical findings: clinically relevant abnormal physical findings (including body temperature) suggesting underlying pathologies or those which could interfere with the objectives of the study.
  • Gastrointestinal disorders likely to influence drug absorption including acute gastrointestinal symptoms (e.g. nausea, vomiting, diarrhoea, heart burn), preceding one week to admission.
  • Laboratory values that are significantly different than the normal reference range and/or are deemed to be of clinical significance by the investigator
  • Presence of reactive disease markers of HIV 1 and II, HBsAg,, HCV or VDRL.
  • Positive for alcohol breath test and/or urine drug screen (barbiturates, benzodiazepines, amphetamine, cocaine, opiates, tetra-hydro cannabinol).
  • Any evidence of organ dysfunction or any clinically significant deviation from the normal, in physical or clinical determinations.
  • History of Diabetes Mellitus or intake of any anti-diabetic medication
  • Diseases: relevant history of renal, hepatic, cardiovascular, respiratory, skin, haematological, endocrine, neurological or gastrointestinal diseases. History of depression, psychosis, schizophrenia or any other severe psychiatric diseases, or epilepsy, or any other illness that may interfere with the aim of the study. History of any significant illness in the 4 weeks preceding the screening
  • Medications: history of intake of any medications including over the counter medications (OTC) during the 4 weeks period prior to dosing with the IMP.
  • Investigational drug trials: participation in the evaluation of any drug in the 3 months prior to the start of the study (dosing with IMP).
  • Blood donation: Subjects who, through completion of this study, would have donated and/or lost more than 300 mL of blood in the past 12 weeks

Note: In case the blood loss is ≤ 200 mL; subject may be dosed 60 days after blood donation or last sample of the previous study

  • Regular smokers who smoke more than 10 cigarettes daily or have difficulty abstaining from smoking for the duration of each study period.
  • History of drug dependence or alcoholics

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01554293

Layout table for location contacts
Contact: Dr Deepak C Chilkoti +91-129-4090 900

Layout table for location information
Fortis Clinical Research Ltd Recruiting
Faridabad, Haryana, India, 121 002
Contact: Dr Deepak C Chilkoti    +91-129-4090 900   
Principal Investigator: Dr Deepak C Chilkoti         
Sponsors and Collaborators
Panacea Biotec Ltd
Layout table for investigator information
Principal Investigator: Dr Deepak C Chilkoti Head-Clinical Operations

Layout table for additonal information
Responsible Party: Panacea Biotec Ltd Identifier: NCT01554293    
Other Study ID Numbers: PBL/CR/2011/05/CT
First Posted: March 14, 2012    Key Record Dates
Last Update Posted: May 16, 2013
Last Verified: May 2013